Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MGNQB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
TrastuzumabA132TCO*A
|
|||||
| Synonyms |
TrastuzumabA132TCO*A
Click to Show/Hide
|
|||||
| Organization |
Vilaxa Biotechnology Co ltd; Europaisches Laboratorium fuer Molekularbiologie EMBL
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1-2
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
CN118574641A-TrastuzumabA132TCO*A-linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
CN118574641A-TrastuzumabA132TCO*A-linker-CN118574641A-TrastuzumabA132TCO*A-payload
|
|||||